本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动包含实际控制人罗卫国和史东伟一致行动关系解除、史东伟在 一定期限内放弃其所持全部公司股份所对应的表决权、罗卫国控制的企业导云资 产拟以现金认购公司 2025 年度向特定对象发行的股票。 综上所述，本次发行完成后，在不考虑其他因素可能导致股本数量变动的情 况下，按照本次发行预案上限测算，罗卫国直接和间接控制上市公司股份比例将 由 12.84%上升至 29.98%。 二、本次发行认购对象基本情况 （一）基本信息 （一）解除一致行动关系 前终止原《一致行动协议》，各方不再保持一致行动关系。解除一致行动关系后， 罗卫国与史东伟所持有的公司股份数量不再合并计算。 （二）放弃表决权 诺在一定期限内不可撤销的同意放弃其所持有的天域生物 32,338,800 股股份所对 应的提案权、表决权、召集权等全部非财产性权利，亦不得委托任何第三方行使。 史东伟表决权放弃后至表决权恢复前，其拥有表决权比例下降至 0.00%。 （三）向特定对象发行股票 导云资产与公司于 2025 ...

Core Viewpoint - Tianyu Biotechnology Co., Ltd. has convened its board meeting to approve the proposal for a private placement of A-shares, indicating the company's compliance with relevant regulations and its readiness to proceed with the issuance [1][2][3]. Board Meeting Details - The board meeting was held on August 25, 2025, with all nine directors present, and the resolutions passed were deemed legal and effective [1]. - The board approved the proposal for the company to issue A-shares to specific investors, confirming that the company meets the necessary conditions for such an issuance [2][3]. Issuance Proposal - The A-shares will have a nominal value of RMB 1.00 per share, and the issuance will be conducted through a private placement [2][3]. - The issuance price is set at RMB 6.55 per share, which is 80% of the average trading price over the previous 20 trading days [3][4]. - The total number of shares to be issued is capped at 71,028,297 shares, which is 30% of the company's total share capital prior to the issuance [4][6]. Use of Proceeds - The funds raised from this issuance will be used to supplement working capital and repay debts, with a total expected amount of up to RMB 526.7353 million [6][12]. - The company plans to utilize up to RMB 61.5 million of previously raised funds temporarily to support its working capital needs [6]. Lock-up Period and Trading - Shares acquired through this issuance will be subject to an 18-month lock-up period post-issuance [5][12]. - After the lock-up period, the shares will be listed for trading on the Shanghai Stock Exchange [6]. Related Transactions and Agreements - The issuance involves a related party transaction with Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Mr. Luo Weiguo [3][12]. - The board has also approved a series of reports and agreements related to the issuance, including feasibility studies and the use of proceeds [9][10][12]. Future Plans and Authorizations - The board has proposed a three-year shareholder return plan for 2025-2027, which will be disclosed in detail [13]. - The company seeks authorization from the shareholders to allow the board to manage all matters related to the issuance, including adjustments based on market conditions [14][15].

Meeting Information - The shareholders' meeting of Tianyu Biotechnology Co., Ltd. is scheduled for September 11, 2025, at 14:00 [1] - The meeting will be held at Bay Valley Technology Park, 1688 Guoquan North Road, Yangpu District, Shanghai [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the trading system or the internet voting platform, with specific time slots for each method on the day of the meeting [2][3] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same class of shares [3][4] - Duplicate votes through different methods will be counted based on the first voting result [4] Agenda Items - The meeting will review several non-cumulative voting proposals, including: - Analysis report on the plan for issuing A-shares to specific targets [2] - Feasibility report on the use of funds raised from the issuance [2] - Agreement on signing a conditional share subscription agreement involving related transactions [2] - Proposal regarding the dilution of immediate returns from the issuance and measures to compensate for this dilution [2] - Authorization for the board of directors to handle matters related to the issuance of A-shares [2][6] Attendance and Registration - Shareholders registered by the close of trading on September 5, 2025, are eligible to attend the meeting [4] - Registration for attendance must be completed by September 9, 2025, with specific documentation required [5] - Travel and accommodation expenses for attending shareholders are self-managed [5]

Core Viewpoint - Tianyu Biotechnology Co., Ltd. is preparing to issue A-shares to specific investors, with the aim of enhancing its financial structure and operational capacity through the raised funds [1][2][5]. Group 1: Meeting Details - The 36th meeting of the fourth Supervisory Board was held on August 25, 2025, with all three supervisors present [1]. - The meeting's procedures complied with relevant laws and regulations, ensuring the legality and validity of the resolutions made [1]. Group 2: Issuance of A-Shares - The Supervisory Board approved the proposal for the company to issue A-shares to specific investors, confirming compliance with the necessary legal requirements [2][3]. - The shares will be issued at a price of 6.55 yuan per share, which is 80% of the average trading price over the previous 20 trading days [3][4]. - The total number of shares to be issued is capped at 71,028,297 shares, which is 30% of the company's total shares prior to the issuance [4][5]. Group 3: Use of Proceeds - The funds raised will be used to supplement working capital and repay debts, with a total expected amount of up to 526.7353 million yuan [5][6]. - The issuance will not only reduce debt financing but also optimize the company's financial structure and enhance its risk resistance [8]. Group 4: Lock-up Period and Shareholder Rights - Shares acquired through this issuance will have an 18-month lock-up period post-issuance [5][6]. - After the lock-up period, the profits will be shared among new and existing shareholders based on their respective shareholdings [6]. Group 5: Related Transactions and Commitments - The issuance involves a related transaction with Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller [9]. - The company has committed to measures to mitigate the dilution of immediate returns for existing shareholders due to this issuance [10]. Group 6: Future Shareholder Returns - A three-year shareholder return plan (2025-2027) has been developed, aligning with the company's strategic goals and external financing environment [11].

Core Viewpoint - The actual controller of Tianyu Biological has changed from a dual control by Luo Weiguo and Shi Dongwei to a single control by Luo Weiguo, following the signing of a termination agreement on August 25, 2025 [1][2] Group 1: Changes in Management and Control - Shi Dongwei has resigned as the president of the company to support Luo Weiguo in managing the company, while continuing to serve as the vice chairman of the board [2] - Shi Dongwei has signed a commitment not to seek control over Tianyu Biological and will not interfere with Luo Weiguo's control [2][3] - After the termination of the joint action relationship, Luo Weiguo holds 37.25 million shares, representing 12.84% of the voting rights [2] Group 2: Fundraising and Share Issuance - The company plans to issue shares to raise no more than 465 million yuan, with the funds used for working capital and debt repayment [2] - The share issuance will increase Luo Weiguo's direct and indirect control of the company from 12.84% to 29.98%, stabilizing his control [3] Group 3: Business Performance and Financial Health - Tianyu Biological has faced continuous losses over the past five years, with net profits of -157 million yuan, -215 million yuan, -312 million yuan, -462 million yuan, and -107 million yuan from 2020 to 2024 [3] - The company's debt ratio has remained high, reaching 75.91% as of the end of the first quarter of 2025 [3]

天域生物科技股份有限公司 简式权益变动报告书 上市公司名称：天域生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：天域生物 股票代码：603717 信息披露义务人：史东伟 住所/通讯地址：上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 B 座 202-203 室 股份变动性质：一致行动关系解除、表决权放弃 签署日期：2025 年 8 月 25 日 天域生物科技股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》 及其他相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在天域生物科技股份有限公司中拥有权益的股 份变动情况。 截至本报告书签署之日，除本报告书披露的信 ...

天域生物科技股份有限公司详式权益变动报告书 天域生物科技股份有限公司 详式权益变动报告书 住所/通讯地址： 上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 B 座 202-203 室天域生物 签署日期：2025 年 8 月 26 日 上市公司名称： 天域生物科技股份有限公司 股票上市地点： 上海证券交易所 股票简称： 天域生物 股票代码： 603717 信息披露义务人 1： 罗卫国 信息披露义务人 2： 上海导云资产管理有限公司 住所/通讯地址： 上海市杨浦区国权北路 1688 弄 12 号 301-2 室 股份变动性质 一致行动关系解除、原一致行动人表决权放弃、认购 上市公司向特定对象发行的股票 天域生物科技股份有限公司详式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理 办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收 购报告书》及其他相关法律、法规和规范性文件编写本报告书。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-063 天域生物科技股份有限公司 关于 2025 年度向特定对象发行 A 股股票预案 披露的提示性公告 特此公告。 天域生物科技股份有限公司董事会 2025 年 08 月 27 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日分 别召开第四届董事会第四十三次会议、第四届监事会第三十六次会议，审议通过 了《关于<公司 2025 年度向特定对象发行 A 股股票预案>的议案》及其他相关议 案。具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）上披露 的《天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票预案》，敬 请广大投资者注意查阅。 公司本次向特定对象发行 A 股股票预案披露事项不代表审批机关对本次向 特定对象发行 A 股股票相关事项的实质性判断、确认或批准，本次向特定对象 发行 A 股股票相关事项的生效和完成尚需公司股东大会审议通过、上海 ...

证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票 方案论证分析报告 二〇二五年八月 | 八、结论 17 | | --- | 释 义 本预案中除另有说明，下列简称具有如下含义： | 公司、上市公司、发行人、 | 指 | 天域生物科技股份有限公司，在上海证券交易所主板上 | | --- | --- | --- | | 天域生物 | | 市，股票代码：603717 | | 本次发行、本次向特定对象 | 指 | 天域生物科技股份有限公司拟向上海导云资产管理有限 | | 发行股票 | | 公司发行股票的行为 | | 认购对象、发行对象、导云 资产 | 指 | 上海导云资产管理有限公司 | | | | 天域生物科技股份有限公司 2025 年度向特定对象发行 A | | 本预案 | 指 | 股股票预案 | | 定价基准日 | 指 | 本次向特定对象发行股票董事会决议公告日 | | 董事会 | 指 | 天域生物科技股份有限公司董事会 | | 股东大会 | 指 | 天域生物科技股份有限公司股东大会 | | 监事会 | 指 | 天域生物科技股份有限公司监事会 | | ...

证券代码：603717 证券简称：天域生物 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完 整性承担个别和连带的法律责任。 2、本预案按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司证券发行注册管理办法》等法律、法规及规范性文件的要求编制。 3、本次向特定对象发行股票完成后，公司经营与收益的变化，由公司自行 负责；因本次向特定对象发行股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之相反 的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行股票相关事 项的实质性判断、确认、批准或核准，本预案所述本次向特定对象发行股票相关 事项的生效和完成尚待公司股东大会审议通过、上海证券交易所审核通过并经中 国证券监督管理委员会同意注册后方可实施。 1 特别提示 天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票预案 二〇二五年八月 发行人声明 ...